You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
|
---|---|
Published in |
BMC Medicine, March 2013
|
DOI | 10.1186/1741-7015-11-59 |
Pubmed ID | |
Authors |
Gemma Bruera, Katia Cannita, Daniela Di Giacomo, Aude Lamy, Thierry Frébourg, Jean Christophe Sabourin, Mario Tosi, Edoardo Alesse, Corrado Ficorella, Enrico Ricevuto |
Abstract |
Prognosis of KRAS wild-type and mutant metastatic colorectal cancer (MCRC) patients (pts) treated with bevacizumab (BEV)-containing chemotherapy is not significantly different. Since specific KRAS mutations confer different aggressive behaviors, the prognostic role of prevalent KRAS mutations was retrospectively evaluated in MCRC pts treated with first line FIr-B/FOx, associating BEV to triplet chemotherapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 19% |
Researcher | 5 | 19% |
Student > Bachelor | 4 | 15% |
Student > Ph. D. Student | 3 | 11% |
Other | 2 | 7% |
Other | 2 | 7% |
Unknown | 6 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 41% |
Agricultural and Biological Sciences | 3 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Social Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 7 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 March 2013.
All research outputs
#20,184,694
of 22,699,621 outputs
Outputs from BMC Medicine
#3,299
of 3,403 outputs
Outputs of similar age
#170,952
of 194,612 outputs
Outputs of similar age from BMC Medicine
#95
of 95 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,403 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,612 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.